Eli Lilly Licenses Amplitude’s RNA Platform for Infectious Disease Vaccines

By Dr. Zubair Khalid, DVM, MS, PhD ·

Eli Lilly Licenses Amplitude’s RNA Platform for Infectious Disease Vaccines

Key Takeaways

  • Eli Lilly has licensed Amplitude Therapeutics' proprietary trans-amplifying RNA (taRNA) platform, a self-amplifying RNA (saRNA) technology, for the development of infectious disease vaccines. This saRNA approach aims to achieve sustained antigen production from a reduced RNA dose.
  • The taRNA platform's mechanism allows for in-situ amplification of the RNA payload within host cells, potentially leading to enhanced immunogenicity and a lower required dose compared to traditional mRNA vaccines. This could translate to simplified manufacturing processes and reduced production costs.
  • This licensing agreement signifies a continued industry trend of major pharmaceutical companies investing in advanced RNA vaccine technologies beyond the established mRNA platforms utilized for COVID-19. The focus is on improving vaccine durability and dose efficiency.
  • The collaboration leverages Eli Lilly's Gateway Labs incubator program, demonstrating its role as a conduit for integrating early-stage biotech innovations, such as Amplitude's taRNA technology, into large-scale pharmaceutical development pipelines.
  • The potential benefits of taRNA technology, including improved dose efficiency and adaptability, are relevant for both human and veterinary vaccine applications, addressing a broad spectrum of infectious disease challenges.

Eli Lilly has entered into a licensing agreement with Amplitude Therapeutics, a resident company at Lilly’s Gateway Labs incubator, to develop trans-amplifying RNA (taRNA) vaccines for infectious diseases. The deal grants Lilly access to Amplitude’s proprietary taRNA platform for research and development.

Amplitude, which operates within Lilly’s Gateway Labs network, will provide its RNA technology to the large pharmaceutical company. The collaboration focuses on applying taRNA, a self-amplifying RNA approach, to create vaccines against infectious disease targets. The specific financial terms of the agreement were not disclosed.

Trans-amplifying RNA technology is designed to enable sustained antigen production from a smaller dose of RNA compared to conventional mRNA vaccines. This could potentially simplify manufacturing and lower costs, while also allowing for more rapid adaptation to emerging pathogens.

Relevance to life sciences: The deal highlights continued interest from major pharmaceutical companies in next-generation RNA vaccine platforms beyond the initial COVID-19 mRNA vaccines. Self-amplifying RNA approaches, including taRNA, aim to improve vaccine durability and dose efficiency, which are important for both human and veterinary medicine. The arrangement also demonstrates how incubator programs, such as Gateway Labs, can serve as pipelines for early-stage biotech innovations into large-scale drug development.

Source: original report